MicroPort CardioFlow Medtech Corporation

DB:72X Stock Report

Market Cap: €230.8m

MicroPort CardioFlow Medtech Valuation

Is 72X undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 72X when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 72X (€0.09) is trading below our estimate of fair value (€0.11)

Significantly Below Fair Value: 72X is trading below fair value, but not by a significant amount.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for 72X?

Other financial metrics that can be useful for relative valuation.

72X key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue1.1x
Enterprise Value/EBITDA-1.6x
PEG Ration/a

Price to Sales Ratio vs Peers

How does 72X's PS Ratio compare to its peers?

The above table shows the PS ratio for 72X vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average2.4x
PUS PULSION Medical Systems
3.7xn/a€131.9m
SBS Stratec
2.1x8.1%€533.6m
EUZ Eckert & Ziegler
3.4x6.0%€933.0m
DRW3 Drägerwerk KGaA
0.3x4.9%€830.1m
72X MicroPort CardioFlow Medtech
4.7x23.5%€2.0b

Price-To-Sales vs Peers: 72X is expensive based on its Price-To-Sales Ratio (4.7x) compared to the peer average (2.4x).


Price to Earnings Ratio vs Industry

How does 72X's PE Ratio compare vs other companies in the European Medical Equipment Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a16.0%
n/an/an/a
No. of CompaniesPS048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a16.0%
n/an/an/a
No more companies

Price-To-Sales vs Industry: 72X is expensive based on its Price-To-Sales Ratio (4.7x) compared to the European Medical Equipment industry average (3.7x).


Price to Sales Ratio vs Fair Ratio

What is 72X's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

72X PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio4.7x
Fair PS Ratio2.5x

Price-To-Sales vs Fair Ratio: 72X is expensive based on its Price-To-Sales Ratio (4.7x) compared to the estimated Fair Price-To-Sales Ratio (2.5x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 72X forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€0.09
€0.21
+129.8%
35.1%€0.26€0.10n/a3
Sep ’25€0.036
€0.26
+627.3%
0.05%€0.26€0.26n/a2
Aug ’25€0.05
€0.26
+429.0%
0.05%€0.26€0.26n/a2
Jul ’25€0.059
€0.26
+347.6%
0.05%€0.26€0.26n/a2
Jun ’25€0.11
€0.31
+190.7%
22.4%€0.41€0.26n/a3
May ’25€0.12
€0.31
+170.7%
22.4%€0.41€0.26n/a3
Apr ’25€0.086
€0.43
+402.6%
39.0%€0.71€0.26n/a4
Mar ’25€0.12
€0.42
+260.4%
36.4%€0.71€0.26n/a5
Feb ’25€0.12
€0.42
+248.5%
36.4%€0.71€0.26n/a5
Jan ’25€0.15
€0.43
+189.5%
36.1%€0.72€0.26n/a5
Dec ’24€0.17
€0.43
+156.3%
36.1%€0.72€0.26n/a5
Nov ’24€0.18
€0.43
+139.1%
36.1%€0.72€0.26n/a5
Oct ’24€0.16
€0.43
+159.5%
36.1%€0.72€0.26n/a5
Sep ’24€0.18
€0.43
+136.8%
32.2%€0.71€0.26€0.0366
Aug ’24€0.25
€0.42
+69.0%
31.7%€0.70€0.28€0.056
Jul ’24€0.20
€0.43
+120.3%
29.3%€0.69€0.29€0.0596
Jun ’24€0.19
€0.43
+127.2%
29.3%€0.69€0.29€0.116
May ’24€0.26
€0.44
+73.0%
29.4%€0.70€0.29€0.126
Apr ’24€0.26
€0.60
+127.6%
56.8%€1.17€0.32€0.0864
Mar ’24€0.36
€0.59
+66.0%
58.5%€1.19€0.33€0.124
Feb ’24€0.40
€0.61
+53.6%
61.3%€1.26€0.33€0.124
Jan ’24€0.30
€0.63
+108.4%
59.6%€1.28€0.33€0.154
Dec ’23€0.32
€0.63
+96.8%
59.6%€1.28€0.33€0.174
Nov ’23€0.30
€0.63
+111.4%
60.5%€1.29€0.34€0.184
Oct ’23€0.28
€0.76
+174.0%
55.0%€1.28€0.34€0.165
Sep ’23€0.37
€0.79
+116.3%
50.4%€1.30€0.38€0.185

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies